GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Price-to-Owner-Earnings

Dare Bioscience (Dare Bioscience) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Price-to-Owner-Earnings?

As of today (2024-06-04), Dare Bioscience's share price is $0.4264. Dare Bioscience does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Dare Bioscience's Price-to-Owner-Earnings or its related term are showing as below:


DARE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.035
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Dare Bioscience's share price is $0.4264. Dare Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.32. Therefore, Dare Bioscience's PE Ratio for today is At Loss.

As of today (2024-06-04), Dare Bioscience's share price is $0.4264. Dare Bioscience's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.32. Therefore, Dare Bioscience's PE Ratio without NRI for today is At Loss.

During the past 12 years, Dare Bioscience's highest PE Ratio without NRI was 1.09. The lowest was 0.00. And the median was 0.34.


Dare Bioscience Price-to-Owner-Earnings Historical Data

The historical data trend for Dare Bioscience's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Price-to-Owner-Earnings Chart

Dare Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dare Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dare Bioscience's Price-to-Owner-Earnings

For the Biotechnology subindustry, Dare Bioscience's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dare Bioscience's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's Price-to-Owner-Earnings falls into.



Dare Bioscience Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Dare Bioscience's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.4264/-0.33
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dare Bioscience  (NAS:DARE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Dare Bioscience Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Dare Bioscience (Dare Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Executives
Sophia Nnenna Ononye-onyia director 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson director, officer: Chef Executive Officer 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair officer: Chief Strategy Officer C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley director 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz director 1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman director C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert officer: Chief Financial Officer C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof officer: SVP, Chief Scientific Officer C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz officer: SVP, Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle director VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal officer: VP, General Counsel C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill officer: Principal Accounting Officer 15 GREENBRIAR CIRCLE, ANDOVER MA 01810

Dare Bioscience (Dare Bioscience) Headlines

From GuruFocus